RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer

© 2017. Introduction: Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. In this randomized, double-blind, placebo-controlled phase III trial we assessed first- or second-line capecitabine with sorafenib or placebo in patients with locally advanced/metastatic HER2-n...

Full description

Bibliographic Details
Main Authors: Baselga, J., Zamagni, C., Gómez, P., Bermejo, B., Nagai, S., Melichar, B., Chan, Arlene, Mángel, L., Bergh, J., Costa, F., Gómez, H., Gradishar, W., Hudis, C., Rapoport, B., Roché, H., Patricia, M., Huang, L., Meinhardt, G., Zhang, J., Schwartzberg, L.
Format: Journal Article
Published: 2017
Online Access:http://hdl.handle.net/20.500.11937/58524

Internet

http://hdl.handle.net/20.500.11937/58524

Similar Items